Elmind Capital LP acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm acquired 210,000 shares of the company’s stock, valued at approximately $363,300,000. Elmind Capital LP owned approximately 0.13% of Entero Therapeutics at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in ENTO. Virtu Financial LLC acquired a new stake in shares of Entero Therapeutics in the third quarter worth approximately $59,000. GSA Capital Partners LLP acquired a new position in Entero Therapeutics in the 2nd quarter valued at $65,000. Persistent Asset Partners Ltd purchased a new position in Entero Therapeutics in the 2nd quarter valued at $198,000. Finally, ADAR1 Capital Management LLC purchased a new position in Entero Therapeutics in the 2nd quarter valued at $3,642,000. Hedge funds and other institutional investors own 12.30% of the company’s stock.
Entero Therapeutics Stock Up 2.3%
Shares of ENTO opened at $3.65 on Wednesday. Entero Therapeutics, Inc. has a 52-week low of $0.32 and a 52-week high of $5.84. The stock has a market cap of $5.80 million, a PE ratio of -2.16 and a beta of 1.19. The firm’s fifty day moving average is $3.84 and its two-hundred day moving average is $3.41.
About Entero Therapeutics
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical?stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility?related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
Featured Stories
- Five stocks we like better than Entero Therapeutics
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding ENTO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report).
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
